Article Versions Notes

Meregalli C, Maricich Y, Cavaletti G, Canta A, Carozzi VA, Chiorazzi A, Newbold E, Marmiroli P, Ceresa C, Diani A, et al. Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models. Cancers. 2021; 13(19):5013. https://doi.org/10.3390/cancers13195013

Meregalli, Cristina, Yuri Maricich, Guido Cavaletti, Annalisa Canta, Valentina A. Carozzi, Alessia Chiorazzi, Evan Newbold, Paola Marmiroli, Cecilia Ceresa, Arthur Diani, and et al. 2021. "Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models" Cancers 13, no. 19: 5013. https://doi.org/10.3390/cancers13195013

Meregalli, C., Maricich, Y., Cavaletti, G., Canta, A., Carozzi, V. A., Chiorazzi, A., Newbold, E., Marmiroli, P., Ceresa, C., Diani, A., Papapetropoulos, S., & Lee, M. S. (2021). Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models. Cancers, 13(19), 5013. https://doi.org/10.3390/cancers13195013